Home > Research > Publications & Outputs > Small molecule inhibitors of Aβ-aggregation and...


Text available via DOI:

View graph of relations

Small molecule inhibitors of Aβ-aggregation and neurotoxicity

Research output: Contribution to Journal/MagazineJournal articlepeer-review

<mark>Journal publication date</mark>1/03/2009
<mark>Journal</mark>Drug Development Research
Issue number2
Number of pages14
Pages (from-to)111-124
Publication StatusPublished
Early online date27/02/09
<mark>Original language</mark>English


Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of Aβ peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and a deficit of cholinergic neurons in the basal forebrain. Presently, only symptomatic therapies are available for the treatment of AD and these therapies have a limited time frame of utility. Amyloid disorders represent the effects of chronic Aβ production and are not a secondary pathological effect caused by a distant trigger; therefore targeting Aβ is a viable pursuit. In this review, we will discuss the various small molecule anti- aggregation inhibitors that have been reported in the literature, with emphasis on compounds that are presently being investigated in clinical trials.